Biosimilars Blog – Page 2

Substitution and Non-Medical Switching: What Pharmacists Need to Know

September 2, 2021

ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The second course in the series,”Substitution and Non-Medical Switching” has been updated to include discussion of the July 28 approval of the first interchangeable biosimilar insulin. The course […]

ASBM Launches Online Biosimilars Course for Pharmacists

June 12, 2021

ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The course is accredited by the American Council on Pharmaceutical Education (ACPE), meaning course credit is available to pharmacists nationwide. The first entry in the series is […]

ASBM Launches Online Biosimilars Course for Pharmacists

June 12, 2021

ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The course is accredited by the American Council on Pharmaceutical Education (ACPE), meaning course credit is available to pharmacists nationwide. The first entry in the series is […]

GaBI Journal: UK Study Shows Need for Improved Identification of Biologics

August 30, 2020

An article in the summer issue of the Journal of the Generics and BIosimilars Initiative (GaBI Journal) emphasizes the need for improved pharmacovigilance with biologic medicines in the UK. The article, entitled “Poor traceability of biologicals in UK ADR reporting indicates the need for improvements to ensure patient safety” covers the UK BIO-TRAC study, which conducted […]

ASBM Exhibits at APhA Annual Meeting

March 26, 2019

From March 22nd-24th, ASBM exhibited at the Annual Meeting and Expo of the American Pharmacists Association (APhA), held in Seattle, Washington.Founded in 1852, APhA is the largest association of pharmacists in the United States, with more than 62,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians as members. ASBM was represented at its booth by Advisory Board Chair Philip Schneider, past president of the […]

ASBM Advisory Board Chair Responds to Mischaracterization of Comments in Washington Post

January 14, 2019

by Philip Schneider, MS FASHP FFIP Advisory Board Chair, Alliance for Safe Biologic Medicines This is to clarify an irresponsible misrepresentation by Christopher Rowland in his article “Patients Stuck In Corporate Fight Against Generic Drugs,” published in the January 9, 2019 edition of the Washington Post. My comments that were misinterpreted in this article […]

ASBM Advisory Board Chair Responds to Mischaracterization of Comments in Washington Post

January 14, 2019

by Philip Schneider, MS FASHP FFIP Advisory Board Chair, Alliance for Safe Biologic Medicines This is to clarify an irresponsible misrepresentation by Christopher Rowland in his article “Patients Stuck In Corporate Fight Against Generic Drugs,” published in the January 9, 2019 edition of the Washington Post. My comments that were misinterpreted in this article […]

ASBM Presents 5-Hour CE Course to NY Pharmacists

October 1, 2018

On September 30th, ASBM presented a 5-hr Continuing Education (CE) course for more than 75 New York area pharmacists. The majority of these attendees were drawn from community pharmacy practice, with a smaller number practicing in health system pharmacy. The CE course was presented in conjunction with The Arnold and Marie Schwartz College of Pharmacy […]

93% of Americans are Now Covered by Biosimilar Substitution Laws

April 1, 2018

Philip J. Schneider, MS FASHP ASBM Advisory Board Chair This week, West Virginia Governor Jim Justice and Wisconsin Governor Scott Walker signed bills updating pharmacy regulations in their respective states. The new laws permit pharmacists to substitute interchangeable biosimilars in place of an originator biologic medicine when they are approved by the FDA. The signing […]

Behind the Numbers: A Q&A With ASBM’s Michael Reilly

December 7, 2017

The Alliance for Safe Biologic Medicines conducts regular surveys to better understand physicians’ perspectives on originator biologics and biosimilars. The organization recently released its 2017 Canadian Prescriber Survey. The survey reveals Canadian physicians’ attitudes on a number of critical policy issues surrounding the approval and use of originator biologics and biosimilars. 83 per […]